

## RECOMMENDATIONS

### Indian Academy of Pediatrics Revised (2021) Guidelines on Prevention and Treatment of Vitamin D Deficiency and Rickets

PIYUSH GUPTA,<sup>1</sup> AASHIMA DABAS,<sup>2</sup> ANJU SETH,<sup>3</sup> VIJAY LAKSHMI BHATIA,<sup>4</sup> RAJESH KHADGAWAT,<sup>5</sup> PRAVEEN KUMAR,<sup>3</sup> S BALASUBRAMANIAN,<sup>6</sup> VAMAN KHADILKAR,<sup>7</sup> HB MALLIKARJUNA,<sup>8</sup> TUSHAR GODBOLE,<sup>9</sup> SRIRAM KRISHNAMURTHY,<sup>10</sup> JAGDISH PRASAD GOYAL,<sup>11</sup> BHANU KIRAN BHAKHRI,<sup>12</sup> AYESHA AHMAD,<sup>13</sup> KUMAR ANGADI,<sup>14</sup> GV BASAVARAJA,<sup>15</sup> BAKUL J PAREKH,<sup>16</sup> ANURA KURPAD,<sup>17</sup> RK MARWAHA,<sup>18</sup> DHEERAJ SHAH,<sup>1</sup> CRAIG MUNNS,<sup>19</sup> HPS SACHDEV<sup>20</sup>

*From Departments of Pediatrics, <sup>1</sup>University College of Medical Sciences, New Delhi; <sup>2</sup>Maulana Azad Medical College, New Delhi; <sup>3</sup>Lady Hardinge Medical College, New Delhi; <sup>4</sup>Departments of Endocrinology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh; <sup>5</sup>Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi; <sup>6</sup>Kanchi Kamakoti CHILDS Trust, Chennai; <sup>7</sup>Hirabai Cowasji Jehangir Medical Research Institute, Jehangir Hospital, Pune, Maharashtra; <sup>8</sup>Senior Consultant Pediatrician, Bangluru; <sup>9</sup>Dr Vasantarao Pawar Medical College, Nashik, Mumbai; <sup>10</sup>JIPMER, Puducherry; <sup>11</sup>All India Institute of Medical Sciences, Jodhpur, Rajasthan; <sup>12</sup>Super Speciality Pediatric Hospital and Post Graduate Teaching Institute, NOIDA; <sup>13</sup>Aligarh Muslim University, Aligarh, Uttar Pradesh; <sup>14</sup>MR Medical College; Gulbarga; <sup>15</sup>Indira Gandhi Institute of Child Health, Bengluru, Karnataka; <sup>16</sup>Bakul Parekh Children's Hospital, Mumbai; <sup>17</sup>Indian Council of Medical Research Expert Committee on Nutrient Requirements of Indians and Scientific Committee, Food Safety and Standards Authority of India, New Delhi; <sup>18</sup>Society of Endocrine Health Care for Elderly Adolescents and Children (SEHEAC), New Delhi; <sup>19</sup>Department of Endocrinology and Diabetes, The Children's Hospital at Westmead, Sydney, Australia; and Pediatric Bone and Mineral Medicine, Sydney Medical School, University of Sydney, Sydney, Australia; <sup>20</sup>Departments of Pediatric and Clinical Epidemiology, Sitaram Bhartia Institute of Science and Research, New Delhi.*

*Correspondence to: Dr Piyush Gupta, Professor and Head, Department of Pediatrics, University College of Medical Sciences, and Guru Teg Bahadur Hospital, Dilshad Garden, Delhi 110095, India. prof.piyush.gupta@gmail.com*

**Justification:** The emerging literature on prevalence of vitamin D deficiency in India, prevention and treatment strategies of rickets, and extra-skeletal benefits of vitamin D suggest the need for revising the existing guidelines for prevention and treatment of vitamin D deficiency in India. **Objectives:** To review the emerging literature on vitamin D prevalence and need for universal vitamin D supplementation. To suggest optimum vitamin D therapy for treatment of asymptomatic and symptomatic vitamin D deficiency, and rickets. To evaluate the extra-skeletal health benefits of vitamin D in children. **Process:** A National consultative committee was formed that comprised of clinicians, epidemiologists, endocrinologists, and nutritionists. The Committee conducted deliberations on different aspects of vitamin D deficiency and rickets through ten online meetings between March and September, 2021. A draft guideline was formulated, which was reviewed and approved by all Committee members. **Recommendations:** The group reiterates the serum 25-hydroxy vitamin D cutoffs proposed for vitamin D deficiency, insufficiency, and sufficiency as <12 ng/mL, 12-20 ng/mL and >20 ng/mL, respectively. Vitamin D toxicity is defined as serum 25OHD >100 ng/mL with hypercalcemia and/or hypercalciuria. Vitamin D supplementation in doses of 400 IU/day is recommended during infancy; however, the estimated average requirement in older children and adolescents (400-600 IU/day) should be met from diet and natural sources like sunlight. Rickets and vitamin D deficiency should be treated with oral cholecalciferol, preferably in a daily dosing schedule (2000 IU below 1 year of age and 3000 IU in older children) for 12 weeks. If compliance to daily dosing cannot be ensured, intermittent regimens may be prescribed for children above 6 months of age. Universal vitamin D supplementation is not recommended in childhood pneumonia, diarrhea, tuberculosis, HIV and non-infectious conditions like asthma, atopic dermatitis, and developmental disorders. Serum 25-hydroxy vitamin D level of >20 ng/mL should be maintained in children with conditions at high-risk for vitamin deficiency, like nephrotic syndrome, chronic liver disease, chronic renal failure, and intake of anticonvulsants or glucocorticoids.

**Keywords:** Cholecalciferol, Infections, Recommendations, Sunlight, Vitamin D supplementation.

**Published online:** December 29, 2021 ; **PII:** S097475591600382

Vitamin D deficiency (VDD) has been reported as an emerging problem globally over the last decade. It remains a significant problem even in tropical countries, despite abundant sunlight [1]. The implications of VDD are believed by many to extend beyond skeletal manifestations to effects on infections, cancers, autoimmune diseases, and mental health conditions [2]. Global Consensus Guidelines for

prevention and treatment of VDD and nutritional rickets in childhood were released in 2016 [3]. The Indian equinox with apparent abundant sun light in most parts of the country, darker skin color with high melanin content, different socio-cultural factors, and genetic variations [4], suggested the need for a guideline relevant to the Indian context; which were released by the Indian Academy of Pediatrics (IAP) in the year 2017 [5].

The Comprehensive National Nutrition Survey (CNNS), by the Ministry of Health and Family Welfare, Government of India involving about 35,000 children aged between 1 to 19 years from all over India, was conducted in 2016-18 [6]. Prevalence of vitamin D deficiency defined as serum 25OHD <12 ng/mL was found to be 14% among children aged 1-4 years, 18% among school age children (5-9 years) and 24% among adolescents (10-19 years) [6], which was below the proportions reported in hospital and community-based studies from India. Gender disparity was observed to be most wide in adolescents with 34% of girls having deficiency as against 14% of boys. Thus, a need was felt to revisit the earlier recommendations.

## OBJECTIVES

The present guidelines re-examine the role of vitamin D supplementation during infancy and childhood in the light of population data on prevalence of vitamin D deficiency. The present guidelines also summarize the recommendations on sunlight exposure for Indian children, and the optimum dosage, schedule, and duration of vitamin D therapy, relevant as per Indian literature. The present guideline is proposed to be used by general practitioners, pediatricians, and epidemiologists working in child health.

## PROCESS

A group of experts were invited under the IAP Action Plan in March, 2020, which consisted of faculty from medical colleges, pediatric practitioners, office bearers of Indian Academy of Pediatrics, and external experts with experience in nutritional epidemiology and clinical research. Six sub-committees were constituted to conduct detailed narrative reviews on the following topics: *i*) Vitamin D deficiency-problem assessment; *ii*) Preventive strategy- maternal and infant supplementation; *iii*) Preventive strategy- natural dietary and sunlight; *iv*) Treatment of VDD and rickets; *v*) Role of vitamin D in extra skeletal health – infections; and *vi*) Role of vitamin D in extra-skeletal health – non-infective conditions.

Data were gathered through semi-structured search strategy with respect to the study question of each respective section. The search was performed on Pub Med and MEDLINE electronic databases.

The initial draft recommendations were discussed with supporting evidence as prepared by the writing committee through emails. The recommendations were then deliberated upon during 10 successive online meetings (March to September, 2021). Delphi technique was used to arrive at a consensus after discussions which helped formulate the final recommendations. An external peer-review was invited by an International expert who provided critical inputs for revising the manuscript.

The level of evidence of each recommendation was graded from 1-5 as per the Oxford Centre for Evidence-Based Medicine (OCEBM) classification [7]. The draft guidelines were circulated for approval to all the members of the Committee for suggestions, if any and final approval.

## RECOMMENDATIONS

The Global Consensus Guidelines and earlier IAP Guidelines have classified vitamin D deficiency, insufficiency, and sufficiency as serum 25-hydroxy vitamin D levels as <12 ng/mL, ≥12-20 ng/mL and >20 ng/mL, respectively [3]. The Group observed that there is a dearth of robust scientific evidence to conclude if these cut-off levels of serum 25(OH)D are valid, especially for skeletal outcomes. Most available Indian studies had used variable cutoffs of 5-20 ng/mL for defining low serum 25(OH)D levels and adverse clinical outcomes [8-35]. Studies have demonstrated an inverse relation between serum parathyroid hormone (PTH) and vitamin D levels, but have not agreed on the inflection point of 25(OH)D level at which PTH begins to rise [36,37]. Most studies were observational and measured only association, thus lacked data on causality, on false positives for adverse skeletal outcomes, inflection point for increase in PTH levels, and correlation of 25(OH)D levels with bone markers and bone histomorphometry. Other confounders like inflammation and adiposity have not been accounted during estimation of burden of VDD in CNNS survey. The Group agreed that in the absence of valid serum 25(OH)D cutoffs, a level of <12 ng/mL may be endorsed as the definition of VDD in concurrence with the earlier guidelines [3,5] and as per the cut off used in the CNNS survey [6]. Serum 25(OH)D >20 ng/mL is considered as desirable/sufficient to provide a buffer for periods of stress, exigency, and seasonal patterns.

The burden of vitamin D deficiency in India shows a marked variation in prevalence across different studies. The prevalence is confounded by factors like age, concomitant calcium deficiency, study setting (community or hospital), study participants (healthy or diseased), geographical location (as per latitude of the area), and sociocultural factors (dressing pattern, dietary intake) [6,32,33,35].

## Vitamin D Toxicity

As the therapeutic indications of vitamin D supplementation increased over the last decade, the possibility of vitamin D intoxication remained an area of concern. The Group felt the need to define urinary excretion cutoffs in addition to serum 25(OH)D levels alone for definition of vitamin D intoxication. The serum 25(OH)D cutoff of >100 ng/mL with associated hypercalcemia and/or hypercalciuria defines vitamin D toxicity. Serum levels between

50-100 ng/mL are unusual without supplementation and should alert the physician to avoid further vitamin D supplementation.

### Estimation of Vitamin D

Automated immunoassay is the most common method utilized by the laboratories world-over [38]. It is simple to use, requires low sample volume and is relatively inexpensive. The major drawback is that it utilizes polyclonal antibodies which in turn get affected by changes in body protein concentrations. Immunoassays; however, cannot differentiate between the two forms of vitamin D, notably 25(OH)D<sub>2</sub> and 25(OH)D<sub>3</sub>. The concentration of 25(OH)D<sub>2</sub> is relatively more in infants and so the estimation of 25(OH)D levels by immunoassay may not be a reliable method during infancy [39]. Another inherent specificity issue with assays utilizing antibodies is cross-reactivity with other vitamin D metabolites; most notably vitamin 24,25(OH)<sub>2</sub>D<sub>3</sub> which constitutes about 10-15% of the total 25(OH)D concentration [40]. These shortcomings can be overcome by utilizing the liquid chromatographic methods either LC-UV or LC-MS/MS [41].

### Consensus statements and recommendations

1.1 *Definition and diagnosis*: Classification of Vitamin D status in children should be based on serum 25(OH)D levels and defined as deficiency <12 ng/mL, insufficiency: 12-20 ng/mL, and sufficiency >20 ng/mL [LOE 2].

1.2 *Hypervitaminosis and vitamin D toxicity*: Diagnosis of vitamin D toxicity can be made in the presence of serum 25(OH)D levels >100 ng/mL with hypercalcemia and/or, hypercalciuria; levels between 50-100 ng/mL should be viewed with caution. Serum PTH levels will be suppressed in cases with vitamin D toxicity [LOE 3].

The normal upper limit for serum calcium: birth to 12 month: 11.3 mg/dL; 1 to 3 year: 11.1 mg/dL; and, 4 to 18 year: 10.7 mg/dL. The normal limits for urine spot calcium: creatinine ratios by age: Up to 6 month: <0.8; 6-12 month: <0.6; ≥24 month: <0.2. Alternatively, 24-hour urinary calcium excretion >4 mg/kg/day.

### 1.3 Prevalence of vitamin D deficiency

1.3.1 Population-based studies measuring serum 25(OH)D remain the best method of estimation of the burden of vitamin D deficiency [LOE 2].

1.3.2 The prevalence of vitamin D deficiency is variable across different parts of India based on geographic location, age group and sociocultural and demographic factors [LOE 2]. National representative data on VDD are not available for infants under 1 year of age. Hospital and community-based studies (using cut offs of 10-20 ng/mL)

have reported vitamin D deficiency in infancy to range from 22-92 % [LOE 3]. Prevalence in older children and adolescents range between 14-24% as per CNNS data.

### 1.4 Estimation of vitamin D levels

1.4.1 Serum 25(OH)D level should be estimated for all clinical purpose where assessment of vitamin D status is required [LOE 5].

1.4.2 Vitamin D levels are best measured with liquid chromatography coupled to ultraviolet (LC-UV) or tandem-mass spectrometry (LC-MS/MS) [LOE 2]. Where LC-UV/LC-MS/MS are unavailable, automated immuno-assay may be used [LOE 2]

### Vitamin D Supplementation for VDD Prevention

The Group noted that the cutoff for vitamin D deficiency in pregnant women at less than 20 ng/mL is higher than that for children (<12 ng/mL) in view of physiological role of vitamin D in fertility and conception [42]; however, there is not enough evidence for 20 ng/mL to be used as a cutoff for the same. The pooled prevalence of low vitamin D levels (≤20 ng/mL) in pregnant women from India was reported as >30%, which seemed as a major public health concern [43]. However, the higher cutoff of defining VDD in pregnancy appears to be the reason for high prevalence.

The World Health Organization (WHO) has provided guidelines on the role of dietary interventions for improving pregnancy outcomes, which did not recommend routine vitamin D supplementation in pregnancy [44,45]. WHO also recommends that the required vitamin D needs should be met by sunlight exposure and dietary intake; the amount of time needed in the sun is; however, not known and depends on many variables [44]. An adequate dietary calcium intake should be encouraged during pregnancy. Calcium should be supplemented in dose of 1200 mg daily in all pregnant and lactating women [46] or in higher doses of 1.5 to 2 grams to improve outcomes for pre-eclampsia in those with low dietary intake [42,47].

The ethical dilemma of stigmatization during pregnancy with nutritional deficiency, unnecessary diagnostic testing and public health concerns like cost-effectiveness and equitable distribution; *vis-à-vis* significant clinical benefits of universal antenatal vitamin D supplementation need to be further explored.

The impact of vitamin D supplementation on other neonatal outcomes was investigated in another systematic review of studies from developing countries. A significant association of maternal VDD (≤20 ng/mL) was seen with low birth weight (LBW), small for gestational age and preterm birth (1 study). There was no association on NICU admission, head circumference or neonatal deaths/

stillbirth (four trials, 1884 women; RR: 0.59, 95% CI: 0.28 to 1.22) [48]. Similar conclusions were observed in other systematic reviews [49,50]. As per a recent Cochrane review, maternal vitamin D supplementation showed a reduction in incidence of LBW without any effect on preterm birth, whereas the combination of vitamin D and calcium, though reduced the risk of LBW but showed an increased risk for preterm birth [51]. Similar positive effect of maternal vitamin D supplementation on birth length and birth weight without any reduction in incidence of SGA and preterm births was observed in another meta-analysis [52]. The recent WHO recommendations for nutritional interventions in pregnancy (2020) concluded little or no effect of vitamin D versus placebo on risk of preterm birth (eight trials, 2938 women; RR: 0.78, 95% CI: 0.48 to 1.27), little or no difference on risk of still birth (four trials, 1884 women; RR: 0.59, 95% CI: 0.28 to 1.22), unclear benefit on low birth weight and neonatal mortality. The administration of calcium with vitamin D or no vitamin D and calcium also did not conclude any significant effect on LBW, neonatal mortality and preterm birth [45].

The available data on prevalence of VDD in infancy mandating routine vitamin D supplementation were reviewed. As mentioned in section 1, the burden of deficiency was highly variable across different studies, with limited literature on impact of routine vitamin D supplementation. However, among different age-groups, infants were considered at higher propensity for VDD as breast milk is a poor source of vitamin D and options of complementary feeding are usually not fortified or rich in vitamin D [53]. The national vitamin D supplementation program providing 400 IU daily to children between 0-3 years showed a decline in prevalence of nutritional rickets in Turkey [54]. A dose of 400 IU daily was found beneficial to achieve serum 25(OH)D levels >20 ng/mL and for prevention of rickets in infants [55-58]. The administration of doses higher than 400 IU did not achieve any significant benefits in bone mineral content or bone markers, and a risk of hypervitaminosis was observed with doses of 1600 IU per day [57,58]. A few randomized controlled trials have shown inferior effect of dose of 400 IU than 800 IU in prevention of VDD in preterm babies [59-63].

Vitamin D supplementation in under-five age group of children was associated with mild improvement in linear growth [mean difference 0.66, 95% CI (-0.37 to 1.68); 3 studies, 240 participants], without any significant effect on length/ height z-scores [64]. Adolescence appears a vulnerable age for manifesting the effects of vitamin D and calcium deficiency as it is the period of maximum bone mass accrual. The prevalence of VDD was higher in adolescents (girls>boys) than other age-groups in the recent CNNS survey [6]. The Committee opined that the estimated

average requirements (EAR) of vitamin D and calcium during adolescence should be met with sunshine and dietary intake without the need of universal vitamin D supplementation (see later). This further refutes the need to screen apparently healthy children for vitamin D deficiency.

A few children may remain at high-risk with their underlying disease states where routine requirements of vitamin D may not be met by natural sources. Such children should receive pharmacological supplementation (minimum 400 IU daily) for prevention of VDD. Routine supplementation with vitamin D was therefore considered as an effective strategy for prevention of vitamin D deficiency in infants and high-risk children.

## Consensus statements and recommendations

### 2.1 Maternal supplementation

2.1.1. Maternal vitamin D status has no bearing on anthropometry outcomes and bone density of the offspring in infancy but may be associated with maternal and neonatal biochemical vitamin D deficiency and neonatal hypocalcemia if the deficiency is severe (LOE 1).

2.1.2 Maternal vitamin D supplementation may improve biochemical vitamin D deficiency in neonates and hypocalcemia in infancy, without any conclusive benefit for other fetal and neonatal outcomes, including neonatal infections, small for gestational age, preterm birth, congenital anomalies, large for gestational age, and fetal/neonatal mortality (LOE 1).

2.1.3 Universal vitamin D supplementation is not recommended during pregnancy (LOE1).

2.1.4 Routine calcium supplementation should be ensured during pregnancy for optimizing maternal and neonatal health outcomes including skeletal health [LOE 1].

### 2.2 Infant and childhood supplementation

2.2.1 We recommend routine vitamin D supplementation in infancy (0-1 years of age) in doses of 400 IU/day. Doses above 400 IU do not offer any additional skeletal benefit during childhood. Higher doses such as 1600 IU daily or above can result in toxicity (LOE2).

2.2.2 A dose of 400 IU/day is safe in preterm babies. Doses of 800 IU/day can achieve desired biochemical levels faster, but the level of evidence and safety data are not enough to make a separate dosing recommendation for preterm babies [LOE3].

2.2.3 Routine vitamin D supplementation is not recommended during childhood and adolescence. Estimated average requirement (EAR) of vitamin D (400-600 IU/day) should be met from sunlight and dietary sources to prevent VDD in these age-groups.

2.2.4 We recommend routine vitamin D supplementation (minimum 400 IU daily) in children with underlying high-risk conditions (**Box I**). Routine screening of apparently healthy children for vitamin D deficiency is not recommended [LOE 5]. Asymptomatic children should be screened only if they are at risk for vitamin D deficiency (e.g., children receiving long term anticonvulsants or glucocorticoids; chronic kidney disease, malabsorption states, children with disabilities, chronic inflammatory diseases, etc) [LOE 5].

### Sunlight and Diet for VDD Prevention

The primary source of vitamin D is endogenous conversion of 7-dehydrocholesterol into previtamin D3 with the help of ultraviolet-B rays (UV-B) of sunlight (wavelength: 290-315nm), which further undergoes isomerization into vitamin D3 (cholecalciferol) by sunlight. This conversion is linear in first 30 min after which there is a non-linear rate of conversion which peaks within 8 hours and is responsible for conversion of 80% of previtamin D3 into cholecalciferol [65]. However, usually only 10-15% of 7-dehydrocholesterol in the skin converts into previtamin D3. Cholecalciferol is converted to active vitamin D3 after successive hydroxylations occurring in liver and kidney, respectively. The previtamin D3 and cholecalciferol later get converted into inert metabolites like lumisterol and tachysterol with a ceiling effect after prolonged duration of sunlight exposure, which prevents development of vitamin D toxicity [66]. The increments in serum 25(OH)D are achieved with every increase in UV irradiance till peak of 55 nmol/L (22 ng/mL) after which the levels get saturated, possibly by the photoisomerization of previtamin D [66,67]. The rise in vitamin D production is higher in those with low baseline serum 25(OH)D levels, and plateaus with constant UVB dosing.

The amount of cutaneous biosynthesis of vitamin D depends on both host and environmental factors. Among the environmental factors, latitude, pollution, cloud cover and intensity of UV irradiance influence vitamin D production [65,68-70]. The UV irradiance should be received directly by skin and not filtered through surfaces

#### Box I High-Risk Conditions Requiring Routine Vitamin D Supplementation in Children

- Non-ambulatory states like cerebral palsy, neuromuscular disorders
- Chronic kidney disease
- Chronic liver disease
- Malabsorption syndromes
- Long-term use of glucocorticoids, antiepileptic drugs, ketoconazole
- Endocrine disorders like hyperparathyroidism
- Disorders with extensive cutaneous involvement

like glass in window panes which can itself absorb UVR. The host factors which determine vitamin D synthesis are age, skin melanin content, single nucleotide polymorphisms in melanin gene, body surface area exposed (clothing), lifestyle and use of sun-barrier measures including topical creams and sunscreens [69,71]. Fitzpatrick skin type is used to classify skin types from I to VI based on their melanin content, where I is the lightest. Indian skin types have higher melanin content than Caucasians and are usually classified as IV or V [72].

VDD remains a significant public health concern even in tropical countries [73]. Studies have found a positive correlation between sunlight exposure and vitamin D production in skin, both from temperate countries as well as India [25,74]. Age is an important host factor which affects this association as the amount of 7-dehydro-cholesterol is constant till old age when it begins to decline [75]. The body surface area (BSA) is also greater for similar exposed body parts in infants and younger children than adolescents or adults. Therefore, young adults demonstrate higher vitamin D levels than older subjects after exposure to the same amount of solar radiation [76]. A rough estimation of BSA for children approximates face, forearms, hands, lower legs and feet to 7-10%, 8%, 4%, 8-12% and 8% BSA, respectively making a cumulative score of approximately 40% in young children (<5 year). The same area in an adolescent or adult would be approximately 30% [77,78].

Sunlight doses have been measured as 'minimal erythema dose (MED)' which is defined as dose of UVR required to produce barely perceptible erythema. UV-B MED in skin type IV and V varies from 40-60 to 60-90 mJ/cm<sup>2</sup> (= 400-600 J/m<sup>2</sup>) which is almost three times the lighter skin type (type I and II) [72]. However, as MED would vary significantly with skin pigmentation, a unit of standard erythemal dose (SED) is commonly used. It is the erythemally weighted radiant UVR equivalent to 100 J/m<sup>2</sup> solar UV index. SED does not rely on erythema and is independent of skin type. One SED is equal to 0.5 times the MED for type I skin [66]. Doses equivalent to MED induce skin damage and may be harmful, instead sub-erythemal doses have shown to be more effective in cutaneous vitamin D production [66]. Also, frequent small UVB dosing were found more efficacious in increasing serum 25(OH)D levels than single large exposures. This could be explored as a feasible option in Indian settings to utilize natural sunlight exposure.

Studies conducted in different ethnic and geographical locations suggest variable duration of sunlight exposure to achieve sufficient serum 25(OH)D levels. The increase in serum 25(OH)D is higher in summer than winter months

[16,31,79-82]. A review suggested 30-45 min of daily sunlight exposure over 12-18% of BSA as sufficient to maintain vitamin D levels in the Indian population [83]. Data available from few other Indian studies in infants, children and adults have been extrapolated to suggest an optimal duration of sunlight exposure, though the rise in serum 25(OH)D may be unpredictable with the underlying host and environmental factors [28,84-86]. This guideline does not endorse artificial UV sources for vitamin D production in children. At present safety data for skin cancers with sunlight exposure in Indian children is unknown [87,88].

Systematic reviews based on adult studies have also shown that serum vitamin D level increases after both, sunlight and vitamin D supplementation; however, the rise is higher and more predictable with vitamin D supplementation than sunlight [89-92]. The rise in serum 25(OH)D was less after long-term sunlight exposure and artificial UVB source than natural sunlight [89]. Compliance to supplementation and sunlight remains a major confounder in estimating the efficacy in natural settings.

Among the dietary sources, vitamin D3 (cholecalciferol) is mainly obtained from animal source like fish, liver, cod liver oil and eggs while vitamin D2 (ergocalciferol) is found in plants, especially mushrooms [93]. The content of vitamin D in Indian foodstuffs can be approximately estimated according to the Indian food composition tables (IFCT), 2017 [94]. There is minimal amount of natural vitamin D in milk (5-40 IU/L) and milk products like cheese and butter (30 IU/100g), which contribute minimally to the RDA [95]. The consumption of skimmed or low-fat milk with reduced fat content of 0.1% and 1% further reduces the amount of vitamin D. Unfortified whole milk, toned milk and full cream milk have higher fat content (>3%) with vitamin D levels between 0.2–0.6 µg/L (8-24 IU/L) [96]. Egg yolk contains variable amount of vitamin D (27-40 IU/egg) and may not be a rich source of the vitamin. Cooking of animal products like boiling eggs, pasteurization of milk, baking and heating meat does not cause significant vitamin D loss. Among fishes, fatty fish like salmon, tuna, mackerel have higher vitamin D content with maximum content in fish liver (1200 µg/kg) than non-fatty fish [96].

Data from CNNS report showed that most (54-56%) children in India consumed vegetarian diets without eggs with higher prevalence of vitamin D deficiency in vegetarians than non-vegetarians [6]. Among the non-vegetarian sources, oily fish, or cod liver oil are unlikely to meet the RDA of vitamin D in amounts likely consumed by children. Data from other developed countries showed low median intake of vitamin D at less than 10 µg/day (400 IU/day) in children and adults [97-101].

Both, vitamin D and calcium intake are crucial for optimal bone health. In the absence of calcium, bone mineralization may remain poor even with replete vitamin D intakes. The major sources for calcium intake in Indian diets are dairy, coarse cereals like ragi, whole legumes like chickpea and green vegetables [13,102]. The nutritional trend in India by National Nutrition Monitoring Bureau (NNMB) from 1975 to 2017 showed that only 37% households in India had daily consumption of >70% RDA of calcium with 44% households having <50% RDA consumption [103]. Likewise, guidelines for Indian children recommend increase in RDA of calcium to 500 mg/day in infancy, 600 mg/day in 1-9 yr old and 800 mg/day in adolescents [46]. However, the dietary insufficiency was substantially overestimated in these publications because: *i*) NNMB primarily sampled the underprivileged, resulting in a bias for national projections; and *ii*) the estimates used the dated Nutritional Requirements for Indians with the Recommended Dietary Allowance (RDA) metric for comparison, which is intended to meet the requirements of 97.5% of the individuals. The updated Nutritional Requirements for Indians, recently published by the Indian Council of Medical Research, use the appropriate metric for comparison, namely the Estimated Average Requirements (EAR), reflecting the average intakes of the populations (needs of half of the population), which are substantially lower than the RDA. The EAR was calculated to meet serum 25(OH)D levels of 40 nmol/L (midpoint between 30-50 nmol/L). The Writing Committee did not have access to the NNMB raw data to provide dietary estimates. Statistical analysis reported an EAR of approximately 400 IU/day in children and 600 IU/day in adolescents (as obtained from natural resources) as sufficient to meet the desired serum vitamin D level [104]. Similar data were not sufficiently available for infancy, suggesting continuing with a recommendation of 400 IU/day as EAR (*details in section 2*).

## Consensus statements and recommendations

### 3.1 Sunlight

3.1.1 Sunlight exposure increases serum 25(OH)D levels and is recommended for children and adolescents across all regions of India to prevent vitamin D deficiency (serum 25(OH)D <12 ng/mL) (LOE 2).

3.1.2 A daily sunlight exposure of 17-30 min in infants and 30-45 min in older children over 15-40% body surface area is recommended at least five times a week during noon (11AM-3PM) for preventing vitamin D deficiency across different regions and seasons (LOE 3.)

3.1.3 Daily application of sunscreens decreases serum vitamin D levels and are not recommended for routine use in children (LOE 3)

3.1.4 The rise in serum 25(OH)D is marginally higher with

vitamin D supplementation than sunlight in adults (LOE 1). Evidence is not enough to recommend superiority or inferiority of vitamin D supplementation over sunlight exposure in preventing vitamin D deficiency in children (LOE5)

3.1.5 The risk of skin cancers with prolonged sunlight exposure in Indian pediatric population is unknown (LOE 3)

### 3.2 Diet

3.2.1 An adequate intake of calcium should be ensured during childhood to meet the dietary requirements. The calcium demand can be met from both dairy and non-dairy (cereal, vegetables etc.) sources (LOE 5).

3.2.2 Foods rich in vitamin D may not contribute sufficiently to meet the vitamin D requirements; however, their intake should be encouraged for consumption as part of a balanced diet within the usual dietary practices (vegetarian or non-vegetarian) (LOE 5).

### Treatment of Rickets and VDD

Symptoms of vitamin D deficiency in children include nutritional rickets, hypocalcemic seizures, tetany, hypocalcemic dilated cardiomyopathy, bony deformities and osteomalacia [3]. There is evidence that all children with nutritional rickets be treated for vitamin D deficiency, irrespective of serum 25(OH)D levels, since they are at increased risk of deformities, muscle weakness and fractures [3,105].

Asymptomatic individuals may be screened if they are at risk for vitamin D deficiency (e.g., children receiving long term anticonvulsants or glucocorticoids; chronic kidney disease, malabsorption states, children with disabilities, chronic inflammatory diseases, etc) [42]. Currently, there is not enough evidence to recommend screening for vitamin D deficiency in healthy population and asymptomatic individuals who are not at risk [106]. The treatment of isolated biochemical derangements in serum vitamin D levels (that do not correlate clinically) is unclear. However, incidentally detected serum 25(OH)D level of less than 12 ng/mL in healthy children should be treated to prevent development of clinical features related to vitamin D deficiency. There is also evidence that children with symptomatic vitamin D deficiency (serum 25(OH)D < 20 ng/mL) without rickets, but with clinical features e.g., hypocalcemic seizures, tetany, hypocalcemic dilated cardiomyopathy, should be treated as for vitamin D deficiency [42].

Both, daily as well as intermittent regimes are efficacious in the management of nutritional rickets [107-115]. Daily doses are more physiological than bolus doses. Lower doses of vitamin D (up to 2000 IU/day) have been

shown to heal rickets in infancy [107,108,116]. However, there is not enough evidence to suggest that intermittent bolus doses of vitamin D are safe in infancy and childhood [110,111]. In some situations, therapy with large cumulative doses spread over a few weeks or months may be more feasible if it is felt that there might be issues with compliance with daily vitamin D therapy. Thus, although daily regimens are preferred, vitamin D dose recommendations for both treatment options, daily as well as bolus regimens is a practical and feasible approach [3]. Bolus doses may be administered at interval of 2-4 weeks comparable to the equivalent daily dose to decrease the risk of hypervitaminosis.

Based on the available evidence [3,107-115], we recommend daily treatment as the first line of management. The issue of safety of bolus regimens in doses equivalent to those used in daily regimes need to be established in well-powered randomized controlled trials in the future, especially in infants.

Oral treatment is the preferred form of vitamin D administration, which more rapidly restores serum 25(OH)D levels than intramuscular (IM) treatment [117,118]. Parenteral administration of mega doses of vitamin D (> 300,000 IU) is not recommended. When single large doses are used, vitamin D3 appears to be preferable compared to D2 because the former has a longer half-life [119]. Vitamin D3 is reported to be better than vitamin D2 to raise serum 25(OH)D levels (mean difference 15.69, 95%CI: 9.46 to 21.93 nmol/L) with average dose per day being a significant predictor, irrespective of the participant demographics, baseline vitamin D levels, total dose, and vehicle of supplementation [120].

Vitamin D oral doses are packaged in India in maximum of 60,000 IU per unit, unlike other developed countries which package as 50,000 IU per unit. Studies have shown comparable efficacy of lower doses of vitamin D, suggesting a feasible dosing regimen of five doses of 60,000 IU for cumulative 300,000 IU. There are no randomized controlled trials on the optimal duration of daily treatment for nutritional rickets in children. Most studies and expert opinion, recommend optimal healing in nutritional rickets after 12 weeks of daily therapy [107,108, 121-125].

Healthcare providers should be aware of the various vitamin D preparations available in India and counsel patients regarding both desirable doses and variability among formulations. Most preparations available in the Indian market contain vitamin D3 [126]. Unsupervised intake of alfacalcidol and calcitriol, which are not recommended for vitamin D deficiency and nutritional rickets, could result in adverse effects including toxicity. Calcitriol has been used in children with hypocalcemic

seizures, along with intravenous calcium gluconate administration in initial treatment to augment clinical improvement.

Oral calcium supplementation (dose 50-75 mg per kg per day to maximum of 500 mg) should be routinely prescribed in combination with vitamin D while treating vitamin D deficiency [121,127,128]. Oral calcium is supplemented frequently as calcium carbonate in children. Preparations with calcium phosphate should be used in younger children and infants who have low phosphate levels to prevent phosphate sequestration with calcium carbonate.

**Monitoring during therapy**

There is insufficient literature to guide the frequency of testing in children receiving vitamin D therapy. There are no randomized trials specifically regarding this issue. In this situation, one may infer that to assess response to therapy as well as to detect toxicity, serum calcium, phosphate, alkaline phosphatase, serum 25 (OH)D levels should be performed at 12 weeks after vitamin D therapy [110,111,114]. Some children may require longer treatment duration for normalization of alkaline phosphatase [129].

We suggest that in a child with rickets, radiographs should be performed at 4 weeks and 12 weeks after vitamin D therapy to look for evidence of healing. The earliest sign of healing would be evident on a radiograph by 4 weeks, an absence of radiological line of healing should alert towards an underlying non-nutritional cause of rickets. If complete radiological healing and normalization of biochemical parameters is not attained in rickets by 12 weeks, therapeutic doses of vitamin D and calcium should be continued. At the same time, the child should be assessed for refractory rickets as per flowchart shown in **Fig. 1**. Maintenance dose of vitamin D should be started once complete healing has been achieved. Urine calcium: creatinine ratio and renal ultrasonogram should be done when there is hypercalcemia or hypervitaminosis D.

**Recommendations**

**4.1 Indications for treatment (Fig. 1)**

4.1.1 Children with nutritional rickets should be treated for

vitamin D deficiency and monitored for therapeutic response (LOE 2) (**Fig. 1** and **Table I**).

4.1.2 Children with clinical pointers towards non-nutritional rickets, should undergo evaluation for etiology of rickets including assessment of serum 25(OH)D levels and parathyroid hormone (**Fig. 1**) (LOE 5).

4.1.3 Children with other symptoms attributable to vitamin D deficiency (e.g., hypocalcemic seizures, tetany, hypocalcemic dilated cardiomyopathy) AND having serum 25(OH)D level < 20 ng/mL should also be treated for vitamin D deficiency (LOE 2).

4.1.4 Incidentally detected low serum 25(OH)D level < 12 ng/mL in healthy children or <20 ng/mL in those at high-risk should be treated (LOE 5), as per protocol for nutritional rickets.

**4.2 Dose, regimes, and duration of vitamin D therapy**

4.2.1 We recommend daily treatment as the first line of management (LOE 2). The safety of intermittent bolus doses of vitamin D is not established, especially in infancy. The issue of safety of regimens involving administration of bolus intermittent doses need to be established in well-powered randomized controlled trials in the future, especially for infants (LOE 5).

4.2.2 Vitamin D (2000 IU/day) is recommended for treatment of nutritional rickets and symptomatic vitamin D deficiency in infants, 3000 IU/day or its equivalent in weekly/monthly bolus doses may be given in children older than 1 year (LOE 2) (**Table I**).

4.2.3 We recommend that the above therapy be given for a minimum of 12 weeks (LOE 2). Some children may require a longer treatment duration for normalization of alkaline phosphatase and serum 25(OH)D levels (LOE 5)

4.2.4 There is paucity of information regarding the role of lower dose of vitamin D (less than 2000 IU/day) for treatment of rickets (LOE 3)


4.2.5 Calcium intake of 50-75 mg/kg/day (not exceeding 500 mg/day) must be ensured either through diet or supplementation in combination with vitamin D (LOE 1).

**Table I Doses for Management of Vitamin D Deficiency or Nutritional Rickets in Children**

Age	Daily dose for 12 wk <sup>a</sup>	Alternative intermittent dose regimen <sup>b</sup>	Maintenance dose (daily) <sup>c</sup>
<6 mo	2000	NA	400
6-12 mo	2000	Equivalent of 2000 IU/day may be given on a monthly or weekly basis	400
>12 mo	3000	60000 IU fortnightly (after every 2 weeks) x 5 doses	600

<sup>a</sup>Reassess response after 12 weeks. Ensure daily calcium intake of 50-75 mg/kg/day, not exceeding 500 mg/day. <sup>b</sup>In certain situations, if compliance is not good, intermittent regimens may be prescribed (in children above 6 months of age only). <sup>c</sup>Ensure daily intake of recommended dose through supplementation or dietary sources. Optimum duration of maintenance vitamin D therapy is not known at present





<sup>a</sup>Treatment of vitamin D deficiency includes calcium supplements along with vitamin D. <sup>b</sup>Monitoring of therapy is discussed in section 4.1. <sup>c</sup>Other investigations as clinically indicated.

**Fig. 1** Algorithm for evaluation of rickets.

### 4.3 Different formulations of vitamin D

4.3.1 Oral treatment with vitamin D is recommended, which more rapidly restores serum 25(OH)D levels and is safer than intramuscular (IM) treatment (LOE 1). We suggest that intramuscular route is to be used only when absorption of oral dose is doubtful e.g., in malabsorption states (LOE 5)

4.3.2 When intermittent bolus doses are used, vitamin D3 is more efficacious than vitamin D2 in improving vitamin D status. For daily treatment, vitamin D3 is only marginally better than vitamin D2 in improving vitamin D status (LOE 1).

4.3.3 Healthcare providers should be aware of the various vitamin D preparations available in India and counsel patients regarding both desirable doses and variability

among formulations (LOE 5).

4.3.4 Alfa-calcidol (1-hydroxycholecalciferol) and calcitriol are not recommended for management of nutritional rickets and vitamin D deficiency (LOE 5).

### 4.4 Monitoring during treatment with vitamin D for nutritional rickets

4.4.1 Radiographs should be obtained at 4 weeks and 12 weeks after vitamin D therapy in rickets to look for evidence of healing (LOE 3).

4.4.2 Serum calcium, phosphate, alkaline phosphatase, serum 25 (OH)D levels should be performed at 12 weeks after vitamin D therapy to measure response and toxicity (LOE 3).

4.4.3 If complete radiological healing and normalization of biochemical parameters (serum 25(OH)D >20-50 ng/mL) is not attained in rickets by 12 weeks, therapeutic doses of vitamin D and calcium should be continued. Maintenance dose of vitamin D should be started once complete healing has been achieved (LOE 5).

4.4.4 Urine calcium:creatinine ratio and renal ultrasonogram should be done when there is hypercalcemia or hypervitaminosis D (as mentioned in section 1) (LOE 5).

### Extra-skeletal Health – Infections

#### 5.1 Vitamin D and pneumonia

There is mounting evidence that vitamin D has an immunomodulating effect and helps in intensifying innate immunity [130]. Many observational studies and systematic reviews have suggested an association between vitamin D deficiency and acute lower respiratory tract infection (ALRTI); however, the same biological effect of vitamin D has not been well documented by experimental studies and systematic reviews of RCTs [131-137].

#### 5.2 Vitamin D and tuberculosis

Growing evidence suggests the immunomodulatory effect of vitamin D in tuberculosis (TB). The exact mechanism of action of vitamin D as an immune regulator is not fully understood [138]. The possible mechanism through which vitamin D helps in preventing *Mycobacterium tuberculosis* (MTB) infection is through the binding of the active form of vitamin D (1,25[OH]<sub>2</sub>D<sub>3</sub>) to VDR. There are many observational studies on the association of vitamin D deficiency and TB in adults, with limited literature in children. A meta-analysis of five clinical trials in which one study addressed the pediatric population, found no evidence of a beneficial effect of vitamin D in the treatment of TB [139]. A systematic review and meta-analysis of eight clinical trials with 1787 patients with active pulmonary TB reported that vitamin D has beneficial effects in improving sputum smear and culture conversion. However, the authors did not present results for the subgroup of children [140].

#### 5.3 Vitamin D and HIV infection

Vitamin D deficiency in HIV leads to decreased innate and adaptive immune response, increase inflammation, and increases the susceptibility of infection due to alteration of monocyte and T cell function [141]. Observational studies in adults and children have reported a low level of vitamin D in HIV-infected children [142-144]. A systematic review, which included thirty studies out of which two were undertaken in children, concluded significant heterogeneity in included studies and the need for further controlled studies to establish a relationship between

vitamin D and HIV infection [145]. There is a paucity of literature on the therapeutic effect of vitamin D on HIV infection in children [146,147].

#### 5.4 Vitamin D and diarrhea

Early studies in infants and children have shown lower levels of vitamin D in children hospitalized with diarrhea than healthy controls, suggesting the role of vitamin D in childhood diarrhea. Lower levels of serum 25 (OH)D were also associated with higher risk of diarrhea with bacteria producing enterotoxins (ETEC) unlike those which had invasive or cytotoxic properties [148]. Most observational and interventional studies have shown association of vitamin D status with number of episodes and severity of diarrhea. However, no causality with VDD or therapeutic efficacy of vitamin D could be established in acute diarrhea in normal-weight or underweight children [26, 31, 149-151]. A recent meta-analysis [135] did not show benefit of vitamin D supplementation in childhood diarrhea with data from two trials.

### Consensus statements and recommendations

5.1.1 Vitamin D levels are lower in children with pneumonia, and a lower level of vitamin D may be associated with higher incidence and severity of pneumonia (LOE 1).

5.1.2 There is no beneficial role of routine vitamin D supplementation in the treatment of pneumonia in children (LOE1).

5.2 Vitamin D levels are significantly lower in children with tuberculosis (LOE 1). There is no advantage of routine vitamin D supplementation in childhood tuberculosis (LOE1).

5.3 An association has been demonstrated between vitamin D deficiency and HIV infection in children (LOE 3). The therapeutic effect of vitamin D supplementation in pediatric HIV is not established. (LOE 2)

5.4.1 Vitamin D levels show poor correlation with incidence and severity of acute diarrhea (LOE2)

5.4.2 Vitamin D supplementation is not beneficial in acute childhood diarrhea (LOE 1)

### Extra-Skeletal Health–Non-Infectious Conditions

*Vitamin D and asthma:* Numerous observational studies had suggested that a low level of vitamin D is associated with an increased risk of asthma in children [152-154]. A systematic review and meta-analysis of twenty-seven studies, out of which eighteen studies included children, indicated a positive correlation of vitamin D and lung functions in both adults and children with asthma [155]. Although epidemiological studies showed a low level of

vitamin D in children with asthma, several meta-analyses on vitamin D supplementation in asthma in children reveal conflicting or limited evidence for protection against exacerbations [156-159].

*Vitamin D and obesity:* Various hypotheses have been proposed to explain possible link of vitamin D level with obesity and metabolic syndrome. Most reviews indicate marginal and insignificant effect, if at all, on few parameters like abdominal obesity, arterial stiffness, and insulin secretion [160-164]. Systematic reviews of intervention studies with vitamin D supplementation in obese adolescents have failed to demonstrate any utility over insulin action [165-167].

*Vitamin D, atopy, and skin conditions:* Vitamin D shows effects on keratinocyte proliferation and differentiation, suppression of inflammatory responses, expression of antibacterial peptides, maintenance of integrity of the permeability barrier, production of cathelicidin and suppression of IgE mediated cutaneous reactions [168]. Incidence of AD was higher among specific vitamin D receptor polymorphism type [169]. However, reasonable number of studies either refuting any such association or even indicating reverse association make it difficult to draw clear conclusions. [170-173].

*Vitamin D and nephrotic syndrome:* Vitamin D deficiency has been established at different types and stages of various form of nephrotic syndromes, further compounded by the ongoing disturbances in the biochemical milieu where there is a loss of vitamin D binding globulin with proteinuria. Patients also exhibit osteoblast suppression and osteoclast induction which further compromise the bone health in these patients. Metabolic bone health may be further compromised with the frequent use of high dose corticosteroids [174-175]. Supplementation of vitamin D is indicated primarily for restoration of the bone health in these patients, which is documented in various studies as improvement in biochemical and radiological parameters of bone health [176,177] and is recommended by international and national guidelines [178,179].

*Vitamin D and childhood developmental disorders:* Maternal vitamin D level and supplementation may affect the fetal brain development as well as the neurodevelopmental outcomes of the offspring [180]. The neuroprotective effect of vitamin D is believed to be secondary to its influences on neuronal calcium homeostasis, release of neuromediators, production of neurotrophins and protection from oxidative damage [181]. Among the various neurodevelopmental disorders affected by vitamin D status, attention deficit hyperactivity disorders (ADHD) and autistic spectrum disorders (ASD) have been studied among children. Several studies indicate higher incidence

of vitamin D deficiency among children affected with ADHD or ASD [182,183]. There is some evidence that optimal vitamin D status is associated with better symptomatology in these children and is advised to be maintained with supplementation [184,185].

### Consensus statements and recommendations

6.1 Vitamin D levels are lower in children with asthma, which may be associated with reduced lung function and asthma exacerbation in children. (LOE 1). Despite that, vitamin D supplementation in children with asthma has not proven to be beneficial (LOE 1).

6.2.1 Vitamin D status is associated with obesity and parameters indicating glycemic handling (LOE 2).

6.2.2 Routine vitamin D supplementation is not recommended in obese children and adolescents for weight and metabolic outcomes (LOE 1).

6.2.3 Vitamin D levels should be maintained in sufficiency range ( $>20$  ng/mL) in children with obesity and metabolic syndrome. The precise dosing amount and frequency cannot be generalized for these patients (LOE 3).

6.3.1 An association between vitamin D status and pathophysiology and clinical presentation in atopic dermatitis is known (LOE 3).

6.3.2 Routine supplementation of vitamin D in children with atopic dermatitis is not recommended as supplementation showing improvement in atopic dermatitis is not proven (LOE 2).

6.4.1 Routine vitamin D and calcium supplementation is recommended in children with nephrotic syndrome to maintain serum 25(OH)D levels above 20 ng/mL (LOE 3).

6.4.2 Serum 25(OH)D concentrations may be monitored annually in children with nephrotic syndrome (LOE 4).

6.5.1 Literature indicates higher incidence of vitamin D deficiency among children with ADHD and ASD (LOE 2).

6.5.2 The direct therapeutic role of vitamin D in ADHD and ASD is not supported by literature. It is advisable to maintain optimal vitamin D status in these disorders (LOE 2).

### CONCLUSIONS

The present guidelines endorse the earlier classification for vitamin D deficiency, insufficiency, and sufficiency as serum 25-hydroxy vitamin D levels as  $<12$  ng/mL,  $\geq 12-20$  ng/mL and  $>20$  ng/mL, respectively. Oral vitamin D supplementation in dosage of 400 IU/day should be continued during infancy. The estimated average requirement of vitamin D of 400 IU/day in childhood and 600 IU/day in adolescents should be met from dietary sources and sunlight. Sunlight exposure is recommended for all

### Box II Areas for Future Research

- Representative survey to estimate prevalence of VDD in infants.
- Population-based studies to explore association of vitamin D deficiency and sufficiency with parathyroid hormone, skeletal and non-skeletal outcomes.
- Predicting response to controlled sunlight exposure in different ages.
- Role of sunlight versus routine vitamin D supplementation.
- Safety of bolus regimens needs to be established in well-powered randomized controlled trials for treatment of nutritional rickets, especially for infants.
- Efficacy of doses of vitamin D lower than 2000 IU/day for treatment of nutritional rickets.
- The optimal time points for monitoring treatment during treatment for nutritional rickets
- The functional benefit of treatment of isolated biochemical derangements in serum vitamin D levels (that do not correlate clinically).

ages, the exact duration and body surface area; however, will differ on host and environmental factors. Oral cholecalciferol with calcium carbonate should be used for treating vitamin D deficiency and rickets in a dose not exceeding 300,000 units across different ages. Daily vitamin D therapy is more physiological than bolus doses, though the Indian experience with daily vitamin D therapy is limited. The Committee suggest treatment of incidentally detected low serum 25(OH)D level <12 ng/mL in healthy children or ≤20 ng/mL in those at high-risk. Vitamin D supplementation only shows an association with common childhood infections and extra-skeletal diseases, not sufficient to mandate routine vitamin D supplementation in children with these conditions.

The committee noted the lack of robust scientific evidence to objectively conclude few aspects of prevention and management of vitamin D deficiency in childhood, and further proposed areas for future research (**Box II**).

*Contributors:* All authors were part of the National Consultative Committee that formulated these guidelines. PG, BJP, GVB: conceived the design and prepared the agenda. AA, TG,AD,SK,JPG,KA,BKB: reviewed the literature for each section in detail and wrote the first draft of the respective sections. VK,VLB,RK,AS,HPS,PK,SB,HBM: moderated the draft recommendations of each respective section and provided critical inputs. DS, AK, RKM were invited experts who provided critical inputs for revision and participated in discussions and manuscript editing. CM: provided external review and critical inputs of the draft recommendations which were incorporated in the successive revisions. HPS, AK, DS, PK,PG provided their inputs in the guidelines. All authors approved the final version.

*Funding:* None; *Competing interests:* None stated.

*Declaration:* The present Committee does not plan to review these guidelines or suggest an expiration date for this version of the guideline.

### REFERENCES

1. Holick MF. Sunlight and vitamin D for bone health and

prevention of autoimmune diseases, cancers, and cardiovascular disease. *Am J Clin Nutr.* 2004;80:1678S-88S.

2. Shah D, Gupta P. Vitamin D Deficiency: Is the pandemic for real? *Indian J Community Med.* 2015;40:215-7.
3. Munns CF, Shaw N, Kiely M, et al. Global Consensus Recommendations on prevention and management of nutritional rickets. *J Clin Endocrinol Metab.* 2016;101:394-415.
4. Holick MF. Health benefits of vitamin D and sunlight: a D-bate. *Nat Rev Endocrinol.* 2011;7:73-5.
5. From Indian Academy of Pediatrics 'Guideline for vitamin D and calcium in children' Committee., Khadilkar A, Khadilkar V, Chinnappa J, et al. Prevention and treatment of vitamin D and calcium deficiency in children and adolescents: Indian Academy of Pediatrics (IAP) Guidelines. *Indian Pediatr.* 2017;54:567-73.
6. Ministry of Health and Family Welfare, Government of India. Comprehensive National Nutrition Survey (CNNS) 2016-2018. Accessed March 9, 2020. Available at: <https://nhm.gov.in/WriteReadData/1892s/1405796031571201348.pdf>
7. Centre for Evidence based medicine. OCEBM Levels of Evidence. Accessed March 12, 2021. Available at URL: <https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebml-levels-of-evidence>
8. Khadilkar AV. Vitamin D deficiency in Indian adolescents. *Indian Pediatr.* 2010; 47:755-6.
9. Marwaha RK, Tandon T, Reddy DRH, et al. Vitamin D and bone mineral density status in healthy school children in North India. *Am J Clin Nutr.* 2005; 82:477-82.
10. Bhalala U, Desai M, Parekh P, et al. Subclinical hypovitaminosis D among exclusively breastfed young infants. *Pediatr.* 2007;44: 897-901.
11. Khadilkar A, Das G, Sayyad M, et al. Low calcium intake and hypovitaminosis D in adolescent girls. *Arch Dis Child.* 2007;92: 1045-9.
12. Harinarayan CV, Ramalakshmi T, Prasad UV, et al. Vitamin D status in Andhra Pradesh: a population-based study. *Indian J Med Res.* 2008;127:211-8.
13. Puri S, Marwaha RK, Agarwal N, et al. Vitamin D status of apparently healthy schoolgirls from two different socioeconomic strata in Delhi: Relation to nutrition and lifestyle. *Br J Nutr.* 2008;99:876-82.
14. Sahu M, Bhatia V, Aggarwal A, et al. Vitamin D deficiency in rural girls and pregnant women despite abundant sunshine in northern India. *Clin Endocrinol.* 2009;70:680-4.
15. Mehrotra P, Marwaha RK, Aneja S, et al. Hypovitaminosis D and hypocalcemic seizures in infancy. *Indian Pediatr.* 2010;47: 581-5.
16. Jain V, Gupta N, Kalaivani M, et al. Vitamin D deficiency in healthy breastfed term infants at 3 months and their mothers in India: Seasonal variation and determinants. *Indian J Med Res.*

- 2011;133:267-73.
17. Khadgawat R, Marwaha RK, Garg MK, et al. Impact of vitamin D fortified milk supplementation on vitamin D status of healthy school children aged 10-14 years. *Osteoporos Int.* 2013;24:2335-43.
  18. Garg MK, Tandon N, Marwaha RK, et al. The relationship between serum 25-hydroxyvitamin D, parathormone and bone mineral density in Indian population. *Clin Endocrinol.* 2014;80:41-6.
  19. Angurana SK, Angurana RS, Mahajan G, et al. Prevalence of vitamin D deficiency in apparently healthy children in North India. *J Pediatr Endocrinol Metab.* 2014;27:1151-6.
  20. Basu S, Gupta R, Mitra M, Ghosh A. A prevalence of vitamin D deficiency in a pediatric hospital of eastern India. *Ind J Clin Biochem.* 2015;30:167-73.
  21. Kumar P, Shenoi A, Kumar RK, et al. Vitamin D deficiency among women in labour and cord blood of newborns. *Indian Pediatr.* 2015;52:530-1.
  22. Naik KD, Preetha R, Ramachandran AM, et al. Cord blood vitamin D levels of term neonates. *Indian Pediatr.* 2015;52:75-6.
  23. Sharawat I, Sitaraman S, Dawman L. Prevalence of vitamin D deficiency among healthy school children in Jaipur district, Rajasthan, India. *Int J Pediatr.* 2015;N-42,801.
  24. Kapil U, Pandey RM, Goswami R, et al. Prevalence of vitamin D deficiency and associated risk factors among children residing at high altitude in Shimla district, Himachal Pradesh, India. *Indian J Endocrinol Metab.* 2017;21:178-83.
  25. Meena P, Dabas A, Shah D, et al. Sunlight exposure and vitamin D status in breastfed infants. *Indian Pediatr.* 2017;54:105-111.
  26. Chowdhury R, Taneja S, Bhandari N, et al. Vitamin D deficiency predicts infection in young north Indian children: a secondary data analysis. *PLoS One.* 2017; 12: e0170509.
  27. Ananada Kesavan TM, Thuruthiyath N, Thomas EP. Subclinical vitamin D deficiency in children from Thrissur, Kerala. *Indian Pediatr.* 2018;55:434-435.
  28. Mandlik R, Kajale N, Ekbote V, et al. Determinants of vitamin D status in Indian school children. *Indian J Endocrinol Metab.* 2018;22:244-248.
  29. Marwaha RK, Mithal A, Bhari N, et al. Supplementation with three different daily doses of vitamin D3 in healthy pre-pubertal schoolgirls: A cluster randomized trial. *Indian Pediatr.* 2018; 55:951-56.
  30. Sarma D, Saikia UK, Baro A. Vitamin D status of school children in and around Guwahati. *Indian J Endocrinol Metab.* 2019;23:81-85.
  31. Ray R, Dabas A, Shah D, et al. Seasonal variation in 25-hydroxyvitamin D and its association with clinical morbidity in healthy infants from Northern India. *Indian Pediatr.* 2019;56:1020-24.
  32. Aparna P, Muthathal S, Nongkynrih B, et al. Vitamin D deficiency in India. *J Family Med Prim Care.* 2018;7:324-30.
  33. Kamboj P, Dwivedi S, Toteja GS. Prevalence of hypovitaminosis D in India and way forward. *Indian J Med Res.* 2018; 54:8-56.
  34. Selvarajan S, Gunaseelan V, Ananda baskar N, et al. Systematic review on vitamin D level in healthy Indian population and analysis of its associated factors. *Indian J Endocrinol Metab.* 2017;21:765-775.
  35. Jeyakumar A, Shinde V. A systematic review and meta-analysis of prevalence of vitamin D deficiency among adolescent girls in selected Indian states. *Nutr Health.* 2019; 25:61-70.
  36. Willet AM. Vitamin D status and its relationship with parathyroid hormone and bone mineral status in older adolescents. *Proc Nutr Soc.* 2005;64:193-203.
  37. Garg U. 25-Hydroxyvitamin D Testing: Immunoassays Versus Tandem Mass Spectrometry. *Clin Lab Med.* 2018;38:439-453.
  38. Carter GD, Berry J, Durazo-Arvizu R, et al. Hydroxyvitamin D assays: an historical perspective from DEQAS. *J Steroid Biochem Mol Biol.* 2018; 177:30-5.
  39. Gallo S, Comeau K, Agellon S, et al. Methodological issues in assessing plasma 25-hydroxyvitamin D concentration in newborn infants. *Bone.* 2014;186-90.
  40. Lai JKC, Lucas RM, Banks E, Ponsomby AL, Ausimmune Investigator Group. *Int Med J.* 2011; 43-49.
  41. Tai SS, Bedner M, Phinney KW. Development of a candidate reference measurement procedure for the determination of 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 in human serum using isotope-dilution liquid chromatography-tandem mass spectrometry. *Anal Chem.* 2010;82:1942-8.
  42. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2011;96:1911-30.
  43. Jeyakumar A, Shinde V, Ravindran R. Pooled estimate of vitamin D deficiency among pregnant women in India: a systematic review and meta-analysis. *J Health Popubl Nutr.* 2021;40:28.
  44. World Health Organization. WHO recommendations on antenatal care for a positive pregnancy experience. Accessed July 12, 2021. Available at URL: <https://www.who.int/publications/i/item/9789241549912>
  45. WHO antenatal care recommendations for a positive pregnancy experience. Nutritional interventions update: Vitamin D supplements during pregnancy. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
  46. Dietary guidelines for Indians - A manual. National Institute of Nutrition. Indian Council of Medical Research. Accessed October 3, 2021. Available at: [http://ninindia.org/DietaryGuide\\_linesfor\\_NINwebsite.pdf](http://ninindia.org/DietaryGuide_linesfor_NINwebsite.pdf)
  47. WHO. Guideline: Calcium supplementation in pregnant women. Geneva, World Health Organization, 2013. Accessed on 03 Nov 2021. Available at URL: [https://www.nhp.gov.in/sites/default/files/pdf/9789241505376\\_eng.pdf](https://www.nhp.gov.in/sites/default/files/pdf/9789241505376_eng.pdf)
  48. van der Pligt P, Willcox J, et al, Daly RM. Associations of maternal vitamin D deficiency with pregnancy and neonatal complications in developing countries: A systematic review. *Nutrients.* 2018;10:640.
  49. Aghajafari F, Nagulesapillai T, Ronksley PE, et al. Association between maternal serum 25-hydroxyvitamin D level and pregnancy and neonatal outcomes: Systematic review and meta-analysis of observational studies. *BMJ.* 2013;346:f1169.
  50. Harvey NC, Holroyd C, Ntani G, et al. Vitamin D supplementation in pregnancy: a systematic review. *Health Technol Assess.* 2014;18:1-190.
  51. Palacios C, Kostiuk LK, Peña-Rosas JP. Vitamin D supplementation for women during pregnancy. *Cochrane Database Syst Rev.* 2019;7:CD008873.
  52. Pérez-López FR, Pasupuleti V, Mezones-Holguin E, et al. Effect of vitamin D supplementation during pregnancy on maternal and neonatal outcomes: A systematic review and meta-analysis of randomized controlled trials. *Fertil Steril.* 2015;103:1278-88.e4.
  53. Ogbó FA, Dhámi MV, Awosémo AO, et al. Regional prevalence and determinants of exclusive breastfeeding in India. *Int Breastfeed J.* 2019;14:20
  54. Ozkan B, Doneray H, Karacan M, et al. Prevalence of vitamin D deficiency rickets in the eastern part of Turkey [published correction appears in *Eur J Pediatr.* 2009 Jan;168(1):101]. *Eur J Pediatr.* 2009;168:95-100
  55. Mutlu GY, Kusdal Y, Ozsu E, Cizmecioglu FM, Hatun S. Prevention of Vitamin D deficiency in infancy: daily 400 IU vitamin D is sufficient. *Int J Pediatr Endocrinol.* 2011;2011:4.
  56. Gallo S, Comeau K, Vanstone C, et al. Effect of different dosages of oral vitamin D supplementation on vitamin D status in healthy, breastfed infants: A randomized trial. *JAMA.* 2013;309:

- 1785-92.
57. Gallo S, Hazell T, Vanstone CA, et al. Vitamin D supplementation in breastfed infants from Montréal, Canada: 25-hydroxyvitamin D and bone health effects from a follow-up study at 3 years of age. *Osteoporos Int.* 2016;27:2459-66.
  58. Holmlund-Suila E, Viljakainen H, Hytinen T, et al. High-dose vitamin D intervention in infants—effects on vitamin D status, calcium homeostasis, and bone strength. *J Clin Endocrinol Metab.* 2012;97:4139-47.
  59. Natarajan CK, Sankar MJ, Agarwal R, et al. Trial of daily vitamin D supplementation in preterm infants. *Pediatrics.* 2014;133:e628-34.
  60. Cho SY, Park HK, Lee HJ. Efficacy and safety of early supplementation with 800 IU of vitamin D in very preterm infants followed by underlying levels of vitamin D at birth. *Ital J Pediatr.* 2017;43:45
  61. Fort P, Salas AA, Nicola T, et al. A Comparison of 3 vitamin D dosing regimens in extremely preterm infants: A randomized controlled trial. *J Pediatr.* 2016;174:132-138.e1.
  62. Munshi UK, Graziano PD, Meunier K, et al. Serum 25 hydroxy vitamin D levels in very low birth weight infants receiving oral vitamin D supplementation. *J Pediatr Gastroenterol Nutr.* 2018;66(4):676-9.
  63. Bronsky J, Campoy C, Braegger C; ESPGHAN/ESPEN/ESPR/CSPEN working group on pediatric parenteral nutrition. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Vitamins. *Clin Nutr.* 2018;37:2366-78.
  64. Huey SL, Acharya N, Silver A, et al. Effects of oral vitamin D supplementation on linear growth and other health outcomes among children under five years of age. *Cochrane Database Sys Rev.* 2020;12:CD012875.
  65. Holick F. Environmental factors that influence the cutaneous production of vitamin D3. *Am J Clin Nutr.* 1995;61:638S-45S.
  66. Webb AR, Alghamdi R, Kift R, Rhodes LE. 100 years of vitamin D: Dose-response for change in 25-hydroxyvitamin D after UV exposure: Outcome of a systematic review. *Endocr Connect.* 2021;10:R248-R266.
  67. Grigalavicius M, Moan J, Dahlback A, Juzeniene A. Vitamin D and ultraviolet phototherapy in Caucasians. *J Photochem Photobiol B: Biol.* 2015;147:69-74.
  68. WHO. Global Solar UV Index: A practical Guide. [https://www.who.int/uv/publications/en/UVIGuide.pdf?ua=1#:~:text=The%20Global%20Solar%20UV%20Index%20\(UVI\)%20describes%20the%20level%20of,takes%20for%20harm%20to%20occur](https://www.who.int/uv/publications/en/UVIGuide.pdf?ua=1#:~:text=The%20Global%20Solar%20UV%20Index%20(UVI)%20describes%20the%20level%20of,takes%20for%20harm%20to%20occur)
  69. Jager N, Schöpe J, Wagenpfeil S, et al. The Impact of UV-dose, body surface area exposed and other factors on cutaneous vitamin D synthesis measured as serum 25(OH)D concentration: Systematic review and meta-analysis. *Anticancer Res.* 2018;38:1165-71.
  70. Khan SR, Whiteman D, Kimlim MG, et al. Effect of solar ultraviolet radiation exposure on serum 25(OH)D concentration: a pilot randomised controlled trial. *Photochem Photobiol Sci.* 2018;17:570-7.
  71. Datta P, Philipsen PA, Olsen P, et al. Pigment genes not skin pigmentation affect UV-B-induced vitamin D. *Photochem Photobiol Sci.* 2019;18:448-58.
  72. Sachdeva S. Fitzpatrick skin typing: Applications in dermatology. *Indian J Dermatol Venereol Leprol.* 2009;75:93-6.
  73. Cashman KD, Sheehy T, O'Neill CM. Is vitamin D deficiency a public health concern for low middle -income countries? A systematic literature reviews. *Eur J Nutr.* 2019; 1-21.
  74. Millen AE, Bodnar LM. Vitamin D assessment in population-based studies: A review of the. *Am J Clin Nut.* 2008;87:1102S-5S.
  75. Mac Laughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. *J Clin Invest.* 1985;76:1536-8.
  76. Harinarayan CV, Holick MF, Prasad UV, Vani PS, Himabindu G. Vitamin D status and sun exposure in India. *Dermato endocrinol.* 2013;5:130-41.
  77. Hettiaratchy S, Papini R. Initial management of a major burn: II-assessment and resuscitation. *BMJ.* 2004;329:101-3.
  78. Specker BL, Ho ML, Oestreich A, et al. Sunshine exposure and serum 25-hydroxyvitamin D concentrations in exclusively breast-fed infants. *J Pediatr.* 1985;107:372-6.
  79. Rockell JE, Green TJ, Murray C, Susan J. Season and ethnicity are determinants of serum of serum 25(OH)D concentration in New Zealand children aged 5-14 yr. *J Nutr.* 2005;135:2602-8.
  80. Rajakumar K, Holick MF, Jeong K, et al. Impact of season and diet on vitamin D status of African American and Caucasian children. *Clin Pediatr (Phila).* 2011;50:493-502.
  81. Raizada N, Goyal A, Singla R, Sreenivas V, Gupta N, Khadgawat R. Changing trend in vitamin D status from 2008 to 2016: An experience from a tertiary care institute in North India. *Indian J Endocrinol Metab.* 2020;24:150-4.
  82. Nurbazlin M, Chee WS, Rokiah P, et al. Effects of sun exposure on 25(OH) vitamin D concentration in urban and rural women in Malaysia. *Asia Pac J Clin Nutr.* 2013;22:391-9.
  83. Harinarayan CV. How to treat Vitamin D deficiency in sun-drenched India - guidelines. *J Clin Sci Res.* 2018; 7:131-40.
  84. Ekbote VH, Khadilkar AV, Mughal MZ, et al. Sunlight exposure and development of rickets in Indian toddlers. *Indian J Pediatr.* 2010;77:61-5.
  85. Marwaha RK, Sreenivas V, Talwar D, et al. Impact of solar ultraviolet B radiation (290-320 nm) on vitamin D synthesis in children with type IV and V skin. *Br J Dermatol.* 2015;173:604-6.
  86. Patwardhan VG, Mughal ZM, Padidela R, et al. Randomized control trial assessing impact of increased sunlight exposure versus vitamin D supplementation on lipid profile in Indian Vitamin D deficient men. *Indian J Endocrinol Metab.* 2017; 21:393-8.
  87. Singh S, Jha B, Tiwary NK, Agrawal NK. Does using a high sun protection factor sunscreen on face, along with physical photoprotection advice, in patients with melasma, change serum vitamin D concentration in Indian conditions? A pragmatic pretest-posttest study. *Indian J Dermatol Venereol Leprol.* 2019; 85:282-6.
  88. Paul SP. Ensuring the safety of sunscreens, and their efficacy in preventing skin cancers: challenges and controversies for clinicians, formulators, and regulators. *Front Med (Lausanne).* 2019;6:195.
  89. Moradi S, Shahdadian H, Rouhani MH. A comparison of the effect of supplementation and sunlight exposure on serum vitamin D and parathyroid hormone: A systematic review and meta-analysis. *Critical Rev Food Sci Nutr.* 2020;60:1881-1889.
  90. Veleva BI, Caljouw MAA, van der Steen JT, et al. The effect of ultraviolet B irradiation compared with oral vitamin D supplementation on the well-being of nursing home residents with dementia: a randomized controlled trial. *Int J Environ Res Public Health.* 2020;17:1684.
  91. Datta P, Philipsen PA, Olsen P, et al. Serum 25(OH)D levels after oral vitamin D<sub>3</sub> supplementation and UV-B exposure correlate. *Photodermatol Photoimmunol Photomed.* 2019;35:344-53.
  92. Wu T, Luo H, Wang R, et al. Effect of vitamin D supplementation and outdoor time on the 25(OH)D level in adolescents. *Wei Sheng Yan Jiu.* 2017;46:207-12 [article in Chinese].
  93. Cashman KD, Kiely M, Seamans KM, Urbain P. Effect of Ultraviolet light-exposed mushrooms on vitamin D status: liquid chromatography-tandem mass spectrometry reanalysis of bio-banked sera from a randomized controlled trial and a systematic

- review plus meta-analysis. *J Nutr.* 2016;146:565-75.
94. National Institute of Nutrition, Indian Council of Medical Research, Ministry of Health and Family Welfare. Indian Food composition tables. 2017. Accessed July 9, 2021. Available from: <http://www.indiaenvironmentportal.org.in/files/file/IFCT%202017%20Book.pdf>
  95. Saggese G, Vierucci F, Prodam F, et al. Vitamin D in pediatric age: Consensus of the Italian Pediatric Society and the Italian Society of Preventive and Social Pediatrics, jointly with the Italian Federation of Pediatricians. *Ital J Pediatr.* 2018;44:51.
  96. Schmid A, Walther B. Natural vitamin D content in animal products. *Adv Nutr.* 2013;4:453:62.
  97. Bailey RL, Dodd KW, Goldman JA, et al. Estimation of total usual calcium and vitamin D intakes in the United States. *J Nutr.* 2010;140:817-22.
  98. Hill TR, O'Brien MM, Cashman KD, et al. Vitamin D intakes in 18–64-y-old Irish adults. *Eur J Clin Nutr.* 2004;58:1509-17.
  99. Freisling H, Fahey MT, Moskal A, et al. Region-specific nutrient intake patterns exhibit a geographical gradient within and between European countries. *J Nutr.* 2010;140:1280-6.
  100. Munasinghe LL, Yuan Y, Willows ND, et al. Vitamin D deficiency and sufficiency among Canadian children residing at high latitude following the revision of the RDA of vitamin D intake in 2010. *Br J Nutr.* 2017; 117, 1052-4.
  101. Petersen RA, Damsgaard CT, Dalskov SM, et al. Vitamin D status and its determinants during autumn in children at northern latitudes: A cross-sectional analysis from the optimal well-being, development and health for Danish children through a healthy New Nordic Diet (OPUS) School Meal Study. *Br J Nutr.* 2016; 115:23-50.
  102. Ekbote VH, Khadilkar AV, Khadilkar VV, et al. Dietary patterns with special reference to calcium intake in 2-16-year-old urban western Indian children. *Indian J Public Health.* 2017;61: 188-93.
  103. Harinarayan CV, Akhila H. Modern India and the tale of twin nutrient deficiency-calcium and vitamin D-nutrition trend data 50 years-retrospect, introspect, and prospect. *Front Endocrinol (Lausanne).* 2019;10:493.
  104. ICMR-NIN Expert Group on Nutrient Requirement for Indians, Recommended Dietary Allowances (RDA) and Estimated Average Requirements (EAR). ICMR-National Institute of Nutrition, Hyderabad, 2020. Accessed November 18, 2021. Available from: [https://www.nin.res.in/RDA\\_Full\\_Report\\_2020.html](https://www.nin.res.in/RDA_Full_Report_2020.html)
  105. Bloom E, Klein EJ, Shushan D, Feldman KW. Variable presentations of rickets in children in the emergency department. *Pediatr Emerg Care* 2004;20:126-130.
  106. Wagner CL, Greer FR. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. *Pediatrics.* 2008;122:1142-1152.
  107. Gordon CM, Williams AL, Feldman HA, et al. Treatment of hypovitaminosis D in infants and toddlers. *J Clin Endocrinol Metab.* 2008;93:2716-21.
  108. Markestad T, Halvorsen S, Halvorsen KS, et al. Plasma concentrations of vitamin D metabolites before and during treatment of vitamin D deficiency rickets in children. *Acta Paediatr Scand* 1984;73:225-231.
  109. Kruse K. Pathophysiology of calcium metabolism in children with vitamin D-deficiency rickets. *J Pediatr* 1995;126:736-741.
  110. Cesur Y, Caksen H, Gundem A, et al. Comparison of low and high dose of vitamin D treatment in nutritional vitamin D deficiency rickets. *J Pediatr Endocrinol Metab* 2003;16:1105-09.
  111. Mittal H, Rai S, Shah D, et al. 300,000 IU or 600,000 IU of oral vitamin D 3 for treatment of nutritional rickets: a randomized controlled trial. *Indian Pediatr* 2014;51:265-72.
  112. Tannous P, Fiscoletti M, Wood N, et al. Safety and effectiveness of Stoss therapy in children with vitamin D deficiency. *J Paediatr Child Health.* 2020;56:81-89.
  113. Tan JK, Kearns P, Martin AC, Siafarikas A. Randomised controlled trial of daily versus stoss vitamin D therapy in Aboriginal children. *J Paediatr Child Health.* 2015;51:626-31.
  114. Mondal K, Seth A, Marwaha R, et al. A randomized controlled trial on safety and efficacy of single intramuscular versus staggered oral dose of 600,000 IU vitamin D in treatment of nutritional rickets. *J Trop Pediatr* 2014;60:203-10.
  115. Shah BR, Finberg L. Single-dose therapy for nutritional vitamin D-deficiency rickets: a preferred method. *J Pediatr.* 1994;125: 487-90.
  116. Shakiba M, Sadr S, Nefei Z, et al. Combination of bolus dose vitamin D with routine vaccination in infants: A randomised trial. *Singapore Med J.* 2010;51:440-5.
  117. Cipriani C, Romagnoli E, Pepe J, et al. Long-term bioavailability after a single oral or intramuscular administration of 600,000 IU of ergocalciferol or cholecalciferol: implications for treatment and prophylaxis. *J Clin Endocrinol Metab.* 2013;98:2709-15.
  118. Zabihyeganeh M, Jahed A, Nojomi M. Treatment of hypovitaminosis D with pharmacologic doses of cholecalciferol, oral vs intramuscular; an open labeled RCT. *Clin Endocrinol (Oxf).* 2013;78:210-16.
  119. Dunlop E, Kiely ME, James AP, et al. Vitamin D food fortification and biofortification increases serum 25-hydroxy-vitamin D concentrations in adults and children: An updated and extended systematic review and meta-analysis of randomized controlled trials. *J Nutr.* 2021;151:2622-35.
  120. Balachandar R, Pullakhandam R, Kulkarni B, Sachdev HS. Relative efficacy of Vitamin D2 and Vitamin D3 in improving Vitamin D status: Systematic review and meta analysis. *Nutrients* 2021;13:3328.
  121. Aggarwal V, Seth A, Marwaha RK, et al. Management of nutritional rickets in Indian children: A randomized controlled trial. *J Trop Pediatr.* 2013;59:127-33.
  122. Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M, Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. *Pediatrics.* 2008;122:398-417.
  123. Pearce SH, Cheetham TD. Diagnosis and management of vitamin D deficiency. *BMJ* 2010;340:b5664.
  124. Shaw NJ, Mughal MZ. Vitamin D and child health. 2. Extra skeletal and other aspects. *Arch Dis Child* 2013;98:368-72.
  125. Munns C, Zacharin MR, Rodda CP, et al; Paediatric Endocrine Group; Pediatric Bone Australasia. Prevention and treatment of infant and childhood vitamin D deficiency in Australia and New Zealand: a consensus statement. *Med J Aust* 2006; 185: 268-272.
  126. Lhamo Y, Chugh PK, Tripathi CD. Vitamin D Supplements in the Indian Market. *Indian J Pharm Sci.* 2016;78:41-7.
  127. Thacher TD, Fischer PR, Pettifor JM, et al. A comparison of calcium, vitamin D, or both for nutritional rickets in Nigerian children. *N Engl J Med.* 1999;341:563-68.
  128. Balasubramanian K, Rajeswari J, Gulab, et al. Varying role of vitamin D deficiency in the etiology of rickets in young children vs adolescents in northern India. *J Trop Pediatr.* 2003;49: 201-6.
  129. Kutluk G, Cetinkaya F, Ba'ak M. Comparisons of oral calcium, high dose vitamin D and a combination of these in the treatment of nutritional rickets in children. *J Trop Pediatr.* 2002;48: 351-53.
  130. White HJ. Vitamin D signaling, infectious diseases, and regulation of innate immunity. *Infect Immun.* 2008;76:3837-43.
  131. Choudhary N, Gupta P. Vitamin D supplementation for severe pneumonia - a randomized controlled trial. *Indian Pediatr.* 2012; 49:449-54.

132. Gupta P, Dewan P, Shah D, et al. Vitamin D supplementation for treatment and prevention of pneumonia in under-five children: A randomized double-blind placebo controlled trial. *Indian Pediatr.* 2016;53:967-76.
133. Somnath SH, Biswal N, Chandrasekaran V, et al. Therapeutic effect of vitamin D in acute lower respiratory infection: a randomized controlled trial. *Clin Nutr ESPEN.* 2017;20:24-28.
134. Singh N, Kamble D, Mahantshetti NS. Effect of vitamin D supplementation in the prevention of recurrent pneumonia in under-five children. *Indian J Pediatr.* 2019; 86:1105-11.
135. Yakoub MY, Salam RA, Khan FR, Bhutta ZA. Vitamin D supplementation for preventing infections in children under five years of age. *Cochrane Database Syst Rev.* 2016;11:CD008824.
136. Das RR, Singh M, Naik SS. Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia. *Cochrane Database Syst Rev* 2018;7:CD011597.
137. Jolliffe DA, Camargo CA Jr, Sluyter JD, et al. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials. *Lancet Diabetes Endocrinol.* 2021; 9:276-292.
138. Coussens AK, Martineau AR, Wilkinson RJ. Anti-Inflammatory and Antimicrobial Actions of Vitamin D in Combating TB/HIV. *Scientifica (Cairo).* 2014;2014:903680.
139. Xia J, Shi L, Zhao L, Xu F. Impact of vitamin D supplementation on the outcome of tuberculosis treatment: a systematic review and meta-analysis of randomized controlled trials. *Chin Med J.* 2014;127:3127-3134.
140. Wu HX, Xiong XF, Zhu M, et al. Cheng DY. Effects of vitamin D supplementation on the outcomes of patients with pulmonary tuberculosis: a systematic review and meta-analysis. *BMC Pulm Med.* 2018;18:108.
141. Jiménez-Sousa MÁ, Martínez I, Medrano LM, Fernández-Rodríguez A, Resino S. Vitamin D in Human Immunodeficiency Virus Infection: Influence on Immunity and Disease. *Front Immunol.* 2018;9:458.
142. Mirza A, Wells S, Gayton T, et al. Vitamin D deficiency in HIV-infected children. *South Med J.* 2016; 109:683-687.
143. Chokeyhaibulkit K, Saksawad R, Bunupuradah T, et al. Prevalence of vitamin D deficiency among perinatally HIV-infected Thai adolescents receiving antiretroviral therapy. *Pediatr Infect Dis J.* 2013;32:1237-9.
144. Rutstein R, Downes A, Zemel B, Schall J, Stallings V. Vitamin D status in children and young adults with perinatally acquired HIV infection. *Clin Nutr.* 2011;30:624-628.
145. Giusti A, Penco GP. Vitamin D deficiency in HIV-infected patients: A systematic review. *Nutr Diet Suppl* 2011;3:101-111.
146. Arpadi SM, McMahon D, Abrams EJ, et al. Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents. *Pediatrics.* 2009;123:e121-6.
147. Eckard AR, O' Riordan MA, Rosebush JC, et al. Vitamin D supplementation decreases immune activation and exhaustion in HIV-1-infected youth. *Antivir Ther.* 2018;23:315-24.
148. Ahmed AM, Soares Magalhaes RJ, Long KZ, et al. Association of vitamin D status with incidence of enterotoxigenic, enteropathogenic and enteroaggregative *Escherichia coli* diarrhoea in children of urban Bangladesh. *Trop Med Int Health.* 2016;21: 973-984.
149. Aluisio AR, Maroof Z, Chandramohan D, et al. Vitamin D supplementation and childhood diarrhea: a randomized controlled trial. *Pediatrics.* 2013;132:e832-40.
150. Hassam I, Kisenge R, Aboud S, Manji K. Association of vitamin D and diarrhoea in children aged less than five years at Muhimbili national hospital, Dar es Salaam: an unmatched case control study. *BMC Pediatr.* 2019;19:237.
151. Sudfeld CR, Manji KP, Smith ER, et al. Vitamin D deficiency is not associated with growth or the incidence of common morbidities among Tanzanian infants. *J Pediatr Gastroenterol Nutr.* 2017;65:467-474.
152. van Oeffelen AAM, Bekkers MBM, Smit HA, et al. Serum micronutrient concentrations and childhood asthma: the PIAMA birth cohort study: Serum nutrients and childhood asthma. *Pediatr Allergy Immunol.* 2011;22:784-93.
153. Brehm JM, Celedón JC, Soto-Quiros ME, et al. Serum Vitamin D Levels and Markers of Severity of Childhood Asthma in Costa Rica. *Am J Respi Crit Care Med.* 2009;179:765-71.
154. Litonjua AA. Vitamin D deficiency as a risk factor for childhood allergic disease and asthma: *Curr Opin Allergy Clin Immunol.* 2012;12:179-85.
155. Liu J, Dong Y, Yin J, et al. Meta-analysis of vitamin D and lung function in patients with asthma. *Respir Res* 2019;20:161.
156. Fares MM, Alkhaled LH, Mroueh SM, Akl EA. Vitamin D supplementation in children with asthma: a systematic review and meta-analysis. *BMC Res Notes.* 2015;8:23.
157. Riverin BD, Maguire JL, Li P. Vitamin D supplementation for childhood asthma: A systematic review and meta-analysis. *PLoS One.* 2015;10:e0136841.
158. Martineau AR, Cates CJ, Urashima M, et al. Vitamin D for the management of asthma. *Cochrane Database Syst Rev* 2016; 356:CD011511.
159. Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D supplementation to prevent asthma exacerbations: a systematic review and meta-analysis of individual participant data [published correction appears in *Lancet Respir Med.* 2018 Jun;6(6):e27]. *Lancet Respir Med.* 2017;5(11):881-890.
160. De Souza Silva J, Pereira SE, Saboya Sobrinho CJ, Ramalho A. Obesity, related diseases and their relationship with vitamin D deficiency in adolescents. *Nutr Hosp.* 2016;33:381.
161. Bhatt SP, Misra A, Sharma M, et al. Vitamin D insufficiency is associated with abdominal obesity in urban Asian Indians without diabetes in North India. *Diabetes Technol Ther.* 2014;16: 392-7.
162. Jamka M, WoŹniewicz M, Jeszka J, et al. The effect of vitamin D supplementation on insulin and glucose metabolism in overweight and obese individuals: systematic review with meta-analysis. *Sci Rep.* 2015;5:16142.
163. Perna S. Is vitamin D supplementation useful for weight loss programs? A systematic review and meta-analysis of randomized controlled trials. *Medicina (Kaunas).* 2019;55: E368.
164. Raed A, Bhagatwala J, Zhu H, et al. Dose responses of vitamin D3 supplementation on arterial stiffness in overweight African Americans with vitamin D deficiency: A placebo controlled randomized trial. *PLoS One.* 2017;12:e0188424.
165. Duan L, Han L, Liu Q, Zhao Y, Wang L, Wang Y. Effects of vitamin D supplementation on general and central obesity: Results from 20 randomized controlled trials involving apparently healthy populations. *Ann Nutr Metab.* 2020; 76:153-164.
166. Jamka M, WoŹniewicz M, Walkowiak J, Bogdański P, Jeszka J, Stelmach-Mardas M. The effect of vitamin D supplementation on selected inflammatory biomarkers in obese and overweight subjects: a systematic review with meta-analysis. *Eur J Nutr.* 2016;55:2163-76.
167. Rafiq S, Jeppesen PB. Body mass index, vitamin D, and Type 2 Diabetes: A systematic review and meta-analysis. *Nutrients.* 2018;10:1182.
168. Wadhwa B, Relhan V, Goel K, Kochhar AM, Garg VK. Vitamin D and skin diseases: A review. *Indian J Dermatol Venereol Leprol.* 2015;81:344-55.
169. Kylyç S, Sylan F, Hız MM, İpýk S, Ögretmen Z, Özdemir Ö.



- Vitamin D Receptor Gene BSMI, FOKI, APAI, and TAQI polymorphisms and the risk of atopic dermatitis. *J Invest Allerg Clin Immunol.* 2016;26:106-10.
170. Byun EJ, Heo J, Cho SH, Lee JD, Kim HS. Suboptimal vitamin D status in Korean adolescents: a nationwide study on its prevalence, risk factors including in cotinine-verified smoking status and association with atopic dermatitis and asthma. *BMJ Open.* 2017;7:e016409.
  171. Robl R, Uber M, Abagge KT, Lima MN, Carvalho VO. Serum vitamin D levels not associated with atopic dermatitis severity. *Pediatr Dermatol.* 2016;33:283-8.
  172. Manousaki D, Paternoster L, Stand IM, et al. Vitamin D levels and susceptibility to asthma, elevated immunoglobulin E levels, and atopic dermatitis: A Mendelian randomization study. *PLoS Med.* 2017;14:e1002294.
  173. Kim MJ, Kim SN, Lee YW, Choe YB, Ahn KJ. Vitamin D status and efficacy of vitamin D supplementation in atopic dermatitis: A systematic review and meta-analysis. *Nutrients.* 2016;8:E789.
  174. Selewski DT, Chen A, Shatat IF, et al. Vitamin D in incident nephrotic syndrome: a Midwest Pediatric Nephrology Consortium study. *Pediatr Nephrol.* 2016;31:465-72.
  175. Cetin N, Gencler A, Sivrikoz IA. Bone mineral density and vitamin D status in children with remission phase of steroid-sensitive nephrotic syndrome. *Saudi J Kidney Dis Transpl.* 2019; 30:853-862.
  176. Singh DN, Krishnamurthy S, Kamalanathan SK, Hari Chandra kumar KT, Sivamurukan P. Three-monthly bolus vitamin D supplements (1000 vs 400 IU/day) for prevention of bone loss in children with difficult-to-treat nephrotic syndrome: A randomised clinical trial. *Paediatr Int Child Health.* 2018;38: 251-260.
  177. Muske S, Krishnamurthy S, Kamalanathan SK, Rajappa M, Hari Chandra kumar KT, Sivamurukan P. Effect of two prophylactic bolus vitamin D dosing regimens (1000 IU/day vs. 400 IU/day) on bone mineral content in new-onset and infrequently-relapsing nephrotic syndrome: a randomised clinical trial. *Paediatr Int Child Health.* 2018;38:23-33.
  178. Trautmann A, Vivarelli M, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. *Pediatr Nephrol.* 2020;35: 1529-1561.
  179. Vasudevan A, Thergaonkar R, Mantan M, et al; Expert group of the Indian Society of Pediatric Nephrology. consensus guidelines on management of steroid-resistant nephrotic syndrome. *Indian Pediatr.* 2021;58:650-666.
  180. Wrzosek M, Łukaszkiwicz J, Wrzosek M, et al. Vitamin D and the central nervous system. *Pharmacol Rep.* 2013;65:271-8.
  181. Alhraiwil NJ, Ali A, Househ MS, Al-Shehri AM, El-Metwally AA. Systematic review of the epidemiology of attention deficit hyperactivity disorder in Arab countries. *Neurosciences (Riyadh).* 2015;20:137-44.
  182. Kočovská E, Andorsdóttir G, Weihe P, et al. Vitamin D in the general population of young adults with autism in the Faroe islands. *J Autism Dev Disord.* 2014;44:2996-3005.
  183. Grant WB, Wimalawansa SJ, Holick MF, et al. Emphasizing the health benefits of vitamin D for those with neurodevelopmental disorders and intellectual disabilities. *Nutrients.* 2015;7: 1538-64.
  184. Cannell JJ. Vitamin D and autism, what's new? *Rev Endocrinol Metab Disord.* 2017;18:183-193.
  185. Jia F, Shan L, Wang B, et al. Bench to bedside review: Possible role of vitamin D in autism spectrum disorder. *Psychiatry Res.* 2018;260:360-365.

#### Annexure 1: List of Participants

Piyush Gupta, *New Delhi, Chairperson*; Aashima Dabas, *New Delhi, Convener*; Anju Seth, *New Delhi*; Vijay Lakshmi Bhatia, *Lucknow*; Rajesh Khadgawat, *New Delhi*. Praveen Kumar, *New Delhi*; S Balasubramanian, *Chennai*; Vaman Khadilkar, *Pune*; HB Mallikarjuna, *Bangalore*; Tushar Godbole, *Nashik*; Sriram Krishnamurthy, *Puducherry*; Jagdish Prasad Goyal, *Jodhpur*; Bhanu Kiran Bhakhri, *Noida*; Ayesha Ahmad, *Aligarh*; Kumar Angadi, *Gulbarga*; GV Basavaraj, *Bangalore*; Bakul J Parekh, *Mumbai*; Anura Kurpad, *New Delhi*; RK Marwaha, *New Delhi*; Dheeraj Shah, *New Delhi*; Craig Munns *Sydney, Australia*; HPS Sachdev, *New Delhi*.